All Oncology News

Belantamab mafodotin plus lenalidomide and dexamethasone induced CRs or better in over half of patients with newly diagnosed multiple myeloma.

Administering the anti-GPRC5D agent MCARH109 and anti-BCMA therapy MCARH125 in tandem was feasible and tolerable in relapsed/refractory multiple myeloma.

The FDA approved subcutaneous pembrolizumab for use in adult and pediatric solid tumor indications approved for intravenous pembrolizumab.

Eque-cel was effective for the treatment of patients with relapsed/refractory multiple myeloma.

Arlo-cel given as a single infusion drove efficacy and was safe in relapsed/refractory multiple myeloma.

D-VRd led to favorable PRO outcomes in patients with newly diagnosed multiple myeloma who had MRD negativity after therapy.

Taletrectinib was approved in Japan for advanced non–small cell lung cancer harboring ROS1 fusions.

The EMA’s CHMP has recommended the approval of subcutaneous pembrolizumab across all indications and perioperative pembrolizumab in locally advanced HNSCC.

Maintenance therapy with belantamab mafodotin, pomalidomide, and dexamethasone was safe and led to durable responses in high-risk myeloma.

The CHMP has recommended the European approval of subcutaneous mosunetuzumab in relapsed/refractory follicular lymphoma.

David Miklos, MD, PhD, discusses the potential role for Orca-T vs standard PTCy after allogeneic transplant in hematologic malignancies.

The global cross-licensing agreement will facilitate work aimed at enhancing the development of inducible switch technologies for cell and gene therapies.

Iberdomide plus daratumumab and dexamethasone yielded deep responses and had a manageable safety profile in transplant-ineligible multiple myeloma.

Data from a phase 2 study suggested that fixed-duration cevostamab is both feasible and safe in patients with heavily pretreated multiple myeloma.

Linvoseltamab plus carfilzomib produced expected toxicities in patients with heavily pretreated, relapsed/refractory multiple myeloma.

Post hoc data demonstrated benefit with daratumumab-based regimens in newly diagnosed, transplant-ineligible myeloma, regardless of frailty changes.

Winship Cancer Institute of Emory University has launched a mobile prostate cancer screening program.

Isa-KRd led to a 74.8% MRD negativity rate in high-risk newly diagnosed multiple myeloma subgroups.

Replimune completed a Type A meeting with the FDA following a complete response letter for RP1 in advanced melanoma.

Vimseltinib earned approval from the European Commission for the treatment of symptomatic, unresectable tenosynovial giant cell tumors.

Lung cancer experts share the evolution of biomarker testing that has led to advances in patient selection for treatment, as well as challenges that future developments may address.

John P. Diaz, MD, discusses the role of minimally invasive surgical approaches for the treatment of patients with uterine cancer.

SHR-4849 showed acceptable safety and early antitumor activity in relapsed small cell lung cancer.

SHR-4849 showed acceptable safety and preliminary antitumor activity in relapsed small cell lung cancer.

ISB 2001 had a manageable safety profile and induced deep, durable responses at active doses in patients with relapsed/refractory multiple myeloma.

The combination of cevostamab, pomalidomide, and dexamethasone was deemed safe with early efficacy signals in relapsed/refractory multiple myeloma.

AACR published its annual Cancer Progress Report, outlining advances in cancer treatment and areas for future improvement.

Early and promising efficacy was shown with elranatamab added to daratumumab/lenalidomide in transplant-ineligible, newly diagnosed multiple myeloma.

Retifanlimab is the first and only immunotherapy agent to receive an indication for the frontline treatment of patients with advanced SCAC.

Optune Lua plus concurrent PD-1/PD-L1 inhibition has been approved in Japan for advanced non–small cell lung cancer after platinum-based chemotherapy.